Serum levels of c-erbb-2 (her-2/neu) in patients with malignant and non-malignant diseases

Tumor Biology

Volumn 18, Issue 3, 1997, Pages 188-196

  Molina, Rafael ^a   Jo, Judith ^a   Filella, Xavier ^a   Bruix, Jordi ^a   Castells, Antoni ^a   Hague, Marta ^a   Ballesta, Antonio M ^a  

^a HOSPITAL CLÍNIC   (Spain)

Author keywords

c erbB 2; HER 2 neu; Oncogenes; Tumor markers; Tumor associated antigens

Indexed keywords

TUMOR ANTIGEN; TUMOR MARKER;

ADULT; ARTICLE; BLOOD LEVEL; CANCER PATIENT; CONTROLLED STUDY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; ONCOGENE C ERB; PRIORITY JOURNAL;

EID: 0030925133     PISSN: 10104283     EISSN: 14230380     Source Type: Journal    
DOI: 10.1159/000218029     Document Type: Article

References (31)

1. Slamon DJ, Godolphin W, Jones LA, Holt JA, Wong SG, Ketli DE, et al: Studies of the HER-2 neu protooncogene in human breast and ovarian cancer, Science 1989:244:707- 712.
2. Molina R, Ciocca R, Tandon AK, Allred DC, Clark GM, Chamness CG, et al: Expression of HER-2/ncu oncoprotein in human breast cancer, A comparison of immunohisto-chemical and Western blot techniques, Anticancer Res 1992; 12: 1965-1972.
3. Tandon AK, Clark GM, Chamness GC, Ulrich A, McGuire WL: HER-2/neu oncogene protein and prognosis in breast cancer, J Clin Oncol 1989;7:1120-1128.
4. Allred DC, Clark GM, Molina R, Tandon AK, Schnitt SJ, Gilchrist KW, ct al: Ovcrexprcssion of HER-2/neu and its relationship with other prognostic factors change during the progression of in-situ to invasive breast cancer, Hum Pathol 1992:23: 974-979.
5. Berger MS, Locher GW, Saurer S, Gullick WJ, Waterfield MD, Groncr B, et al: Correlation of c-erbB2 gene amplification and protein expression in human breast carcinoma with nodal status and nuclear grading, Cancer Res 1988:48:1238- 1243.
6. Marx D, Schauer A, Reichc Ch, May A, Ummrnhofer L, Reles A, et al: c-erbB2 expression in correlation to other biological parameters of breast cancer, J Cancer Res Clin Oncol 1990:116:15-20.
7. Molina R, Filella X, Segui MA, Cli-ment MA, Perez-Picanol E, Alonso C, et al: Oncogenic proteins and prognostic correlations in breast cancer, In Vivo 1993;7:585-590.
8. Allred DC, Clark GM, Tandon AK, et al: HER-2/neu in node-negative breast cancer: Prognostic significance of ovcrexprcssion influenced by the presence of in situ carcinoma, J Clin Oncol 1992:4:599-605.
9. Mori S, Mori Y, Mukaiyama T, Ya-mada Y, Sonobe Y, Matsushita H, et al: In vitro and in vivo release of soluble erb B-2 protein from human carcinoma cells, Jpn J Cancer Res 1990;81:489-494.
10. Zabrecky JR, Lam T, McKenzie SJ, Carney W: The extracellular domain of p 185 neu is released from the surface of human breast carcinoma cell, SK-BR-3, J Biol Chent 1991;266: 1716-1720.
11. Pupa SM, Menard S, Morelli D, Pozzi B, De Palo G, Colnaghi MI: The extracellular domain of the c-erb B2 oncoprotein is released from tumor cells by proteolytic cleavage, Oncogene 1993;8:2917-2923.
12. McKenzie SJ, De Sombre KA, Bast BS, Hollis DR, Whitaker RS, Ber-chuck A, et al: Serum levels of HER-2/neu (C-erbB 2) correlate with overexpression of pi84 neu in human ovarian cancer, Cancer 1993; 71:3942-3946.
13. Narita T, Funahashi H, Satoh Y, Takagi H: C-erbB-2 in the sera of breast cancer patients, Breast Cancer Res Treat 1992;24:97-102.
14. FIGO: Changes in definitions of clinical staging for carcinoma of the cervix and ovary, Am J Obstet Gynecol 1987;156:236-240.
15. Zelen M: Keynote address on biostatistics, Cancer Chcmother Rep 1973;4:31-42.
16. UICC (International Union Against Cancer): TNM Atlas: Illustrated Guide to the TNM/pTNM Classification of Malignant Tumors, ed 3, rev 2, Berlin, Springer, 1992.
17. Molina R: HER-2/neu oncogene in breast cancer, J Nucl Med Allied Sei 1990;34:120-127.
18. McCann A, Dervan PA, Johnston PA, Gullick WJ, Carney DN: C-erbB-2 oncoprotein expression in primary human tumors, Cancer 1990:48:1517-1520.
19. Schneider PM, Hung MC, Chiocca S, Manning J, Zhao X, Fang K, Roth JA: Differential expression of the c-erbB-2 gene in human small cell and non-small cell lung cancer, Cancer Res 1989;49:4968-4971.
20. Molina R, Filella X, Torres MD, Ballesta AM, Mengual P, Cases A, Balaguc A: SCC antigen measured in malignant and nonmalignant diseases, Clin Chem 1990:36:251-254.
21. Molina R, Filella X, Bruix J, Mengual P, Bosch J, Calvet X, Jo J, Ballesta AM: Cancer antigen 125 in serum and ascitic fluid of patients with liver diseases, Clin Chem 1991; 37:1379-1383.
22. Lehmann FG, Wegener T: Alphafetoprotein in liver cirrhosis, 11, Early detection of hepatoma; in Lehmann FG (ed): Carcinoembryonic Proteins, Amsterdam, Elsevier North Holland Press, 1979, pp 231-243.
23. Lowestein MS, Zamcheck N: Carcinoembryonic antigen (CEA) levels in benign gastrointestinal disease status, Cancer 1978;42:1412-1418.
24. Cases A, Filella X, Molina R, Ballesta AM, Lopez-Revcrt J, Revert L: Tumor markers in chronic renal failure and hemodialysis patients, Nephron 1991;37:1379-1383.
25. Filella X, Molina R, Jo J, Bcdini JL, Joseph J, Ballesta AM: Tumor associated gl\coprotein-72 (TAG-72) levels in patients with non-malig-nant and malignant diseases, Bull Cancer 1992;79:271-277.
26. Molina R, Agusti C, Filella X, Jo J, Joseph J, Gimenez N, Ballesta AM: Study of a new tumor marker CY-FRA 21-1 in malignant and nonmalignant diseases, Tumor Biol 1994; 15:318-325.
27. Ballesta AM, Molina R, Filella X, Jo J, Gimenez N: Carcinoembryonic antigen in stating and follow-up of patients with solid tumors, Tumor Biol 1995;16:32-41.
28. Ritts RE, Del Villano BC, Go VLW, Heberman RB, Klug TL, Zurawski VR: Initial clinical evaluation of an intmunoradiometric assay for CA 19.9 using the NCI serum bank, Int J Cancer 1984;33:339-345.
29. Molina R, Zanon G, Filella X, Moreno F, Jo J, Daniels M, et al: Use of serial carcinoembryonic antigen and CA 15.3 assays in detecting relapses in breast cancer patients, Breast Cancer Res Treat I995;36: 41-48.
30. Colomcr R, Ruibal A, Salvador L: Circulating tumor marker levels in advanced breast carcinoma correlate with the extent of metastatic disease, Cancer 1989;64:1674-1681.
31. Molina R, Ballesta AM: Evaluation of several tumor markers (MCA, CA 15.3, BCM and CA 549) in tissue and serum of patients with breast cancer; in Ceriani RL (ed): Breast Epithelial Antigens, Molecular Biology to Clinical Applications, New York, Plenum Press, 1991, pp 161-168.